Virus isolated from an outbreak of poliomyelitis in Finland has been examined serologically and at the molecular level. The causative agent was an antigenically unusual strain of type 3 poliovirus, which was unrelated to the strains used to manufacture either live or killed poliovaccines. It is likely that the antigenic properties of the virus played a part in establishing a limited outbreak of poliomyelitis in a vaccinated population.
INTRODUCTION
A small outbreak of paralytic poliomyelitis occurred in Finland between August 1984 and January 1985. Type 3 poliovirus was responsible for nine cases of paralytic disease and was also isolated from some 100 of 700 faecal specimens collected from healthy subjects living in various parts of the country (Weekly Epidemiological Record, 1985) . Vaccination against poliomyelitis in Finland is based on the use of inactivated vaccines and prior to the recent outbreak, the last indigenous case of the disease was in 1961. No polioviruses had been isolated from individuals since 1964, and no polioviruses were found in a systematic search of sewage specimens obtained in Finland between 1971 and 1984 (Lapinlemu & Stenvik, 1981 . The studies reported here were directed towards identifying the reason for the outbreak of poliomyelitis in a well-vaccinated population and suggest that a major contributory factor was the antigenically unusual nature of the virus. A detailed report on the outbreak and subsequent measures taken will be published separately (T. Hovi et al., in preparation) .
METHODS
Virus strains. Seven of the virus strains studied were isolated in Finland from faecal samples obtained from cases of disease (reference numbers 60212, 04381, 26101, 26063, 71385, 2575, 72943) and three from healthy contacts (23127, 02575, 22650) . In addition five other strains were included, namely the Sabin vaccine strain (P3 Leon 12a ~ b), the type 3 virus used as the seed for the inactivated vaccine used in Finland (Saukett E) and that used as the seed for the vaccine used in the Netherlands (Saukett F) and two unrelated paralytic strains P3/30/USA/52 and P3/2041/Spain/83.
Oligonucleotide mapping. Oligonucleotide mapping was carried out as previously described (Minor, 1980 (Minor, , 1982 . RNA sequencing. RNA sequencing was performed by the dideoxy chain termination method using reverse transcriptase and synthetic primers as described (Evans et aL, 1983) .
Serum samples. All serum samples were taken prior to the start of the outbreak. They included 20 sera from 12-year-old children supplied by Dr M. Bottiger, Sweden, 23 sera from children aged 3 to 6 years supplied by Dr L. Flugsrud, Norway and 23 sera from Dr K. Lapinlemu, Finland, collected 1 month after the second of two doses of inactivated poliovaccine (IPV) from children aged 1 to 2 years.
Monoclonal antibodies. The monoclonal antibodies used in the study were generated and characterized under the auspices of a WHO collaboration (Ferguson et al., 1986) .
Monoclonal antibodies 175, 495, 520 were generated at the National Institute for Biological Standards and D. I, MAGRATH AND OTHERS Control (NIBSC) in hybridoma fusions involving mice immunized with Sabin type 3 virus, and 789 and 792 in hybridoma fusions involving mice immunized with P3/23127/Finland/84, a strain from the Finnish outbreak (P. D. Minor et al., unpublished) . Monoclonal antibodies 3a, 3b, Ilia, 3o and III 0 were generated at Institut Pasteur from mice immunized either with the Sabin strain or the wild Saukett strain of poliovirus type 3 (Crainic et al., 1983) .
Neutralization tests. The sera were assayed for neutralizing antibody as described previously (Crainic et al., 1983; Bainton et al., 1979) .
Immunization of animals. Guinea-pigs were inoculated intramuscularly with 0-2 mi of sucrose gradient-purified virus (approximately 108 p.f.u.). Blood was collected for assay 6 days later.
RESULTS

T1 RNase oligonucleotide mapping of virus strains
Oligonucleotide maps of RNA from three strains of type 3 virus are shown in Fig. 1 . They were the Sabin vaccine strain (Fig. 1 a) , a strain from the outbreak P3/23127/Finland/1984 (Fig.  lb) , and the type 3 poliovirus strain Saukett E which is the seed for the inactivated vaccine used in Finland (Fig. 1 c) . All three maps were distinct, demonstrating that the viruses were unrelated strains (Minor, 1980 (Minor, , 1982 Nottay et al., 1981) .
The outbreak of poliomyelitis in Finland was thus not caused by a vaccine strain of type 3 poliovirus.
Oligonucleotide maps have been obtained for RNA from other strains isolated in the course of the outbreak (data not shown). All the strains were clearly related although there were small but significant differences between maps of different isolates. This was consistent with the findings of others of genomic variation of poliovirus in the course of an epidemic (Nottay et al., 1981) . However, virus isolates from the paralytic cases were not more closely related to each other than to the other strains examined.
Reaction of isolates with monoclonal antibodies
The reactions of five representative antibodies from the NIBSC and five from the Institut Pasteur in neutralization tests with ten of the strains from the outbreak are summarized in Table  1 . The Finnish strains presented were selected from a large number tested and include all the paralytic cases, and all four of the patterns of reaction which were observed. None of the Finnish viruses tested was neutralized by either strain-specific or broadly reacting poliovirus type 3 neutralizing monoclonal antibodies from the Institut Pasteur. Most of the isolates failed also to be neutralized by monoclonal antibodies 175, 495 and 520 generated against Sabin 3 virus. However, two exceptions were noted, namely strain 02575 which reacted with all three antibodies and 71385 which reacted only with antibody 520. All viruses in the test were neutralized by antibody 792 which was produced by a fusion involving a mouse immunized with 23127. Only the immunizing virus was neutralized by antibody 789, produced in the same fusion as 792. Table 1 also includes the Sabin vaccine strain, Saukett E and two other strains from unrelated paralytic cases. Antibody 789 failed to neutralize any of the four strains, whereas antibody 520 failed to neutralize 30/USA/52. Antibody 30 neutralized the Sabin strain but not Saukett, while antibody IIio neutralized Saukett E but not the Sabin strain. All other strains were neutralized by all other antibodies. The generally broad reaction of poliovirus type 3 monoclonal antibodies with different virus strains has been reported previously (Ferguson et al., , 1985 . The isolates from the Finnish outbreak were therefore antigenically very different from most others examined. Antigenically unusual strains resistant to neutralization by broadly reactive monoclonal antibodies have been occasionally identified previously (Ferguson et al., , 1985 .
Amino acid sequences of a major antigenic locus
We have previously shown that a major antigenic locus for the neutralization of type 3 poliovirus is found between amino acids 89 and 100 of VP 1, one of the major structural proteins of the virus (Minor et al., 1985) . This site/is the target of most neutralizing monoclonal Poliovirus type 3 variant antibodies induced with infectious poliovirus. The base sequences of this region of the genomic RN A of ten isolates from the Finnish outbreak were examined by primer extension sequencing. The differences between the sequences of the Finnish strains and the corresponding sequence of the Sabin strain of type 3 poliovirus are summarized in Table 2 . Eight of the ten isolates had alanine 99 substituted by valine, and arginine 98 replaced by either serine (strain 22650) or asparagine (the remaining seven strains). All these strains had the same reaction patterns with the monoclonal antibodies listed in Table 1 , except for strain 23127 which had a third mutation where threonine 96 was substituted by alanine. Two strains had only one mutation in which the arginine at position 98 was replaced by either lysine (02575) or asparagine (71385). Three of the five patterns of substitution were associated with a unique pattern of antigenic reaction, as shown in Table 1 . The remaining patterns of substitution which involved the replacement of a valine for alanine 99 and the substitution of either a serine or an asparagine for arginine 98 both produced the same pattern of antigenic reaction. The region of VP1 considered in Table 2 has been shown to be well conserved in most wild-type viruses (Ferguson et al., 1985) . 
Reaction of isolate 23 127 with human sera
Sera collected before the Finnish outbreak were obtained from Finland, Norway and Sweden and analysed for their ability to neutralize the Saukett E and 23127 viruses, the latter being the most antigenically drifted of the Finnish strains. The results are summarized in Table 3 , and indicate that in all cases the geometric mean titres of the different sera were less against 23127 than against Saukett E. This was especially striking for the Finnish sera.
When the sera were examined separately, over 80~ had a titre of greater than 1:4 for Saukett E from all three countries. However, when 23127 was used as the challenge strain, only 39~ of Finnish sera had a titre greater than 1:4, while 61 ~o of Norwegian sera and 95 ~ of the Swedish sera had a titre of greater than 1:4. The unusual antigenic character of the virus as detected by monoclonal antibodies was thus also evident in its reactions with polyclonal human sera from both Finland and Norway.
Response of animals to immunization
Groups of four guinea-pigs were immunized with sucrose gradient-purified infectious virus (D antigen) and bled 6 days later. The sera were then titrated using homologous and heterologous viruses, and the geometric mean titres of each group are given in Table 4 . Animals immunized with the type 3 Sabin vaccine strain, Saukett E or 02575 developed high titres against each of these viruses, but far lower titres against 23127. Conversely, animals immunized with 23127 developed high titres when screened with homologous virus, but essentially no antibody when screened with the Sabin type 3 strain, Saukett E or 02575. Saukett F is a strain of type 3 virus used for the manufacture of type 3 inactivated vaccine in the Netherlands, and it produced the same results as Saukett E in the immunized animals, inducing low levels of antibody against 23127, and being poorly neutralized by sera induced by 23127.
DISCUSSION
The data reported here describe the antigenic and molecular properties of a series of strains of type 3 poliovirus isolated from an epidemic which occurred in Finland in a population with a level of vaccine acceptance greater than 97~o (Lapinlemu & Stenvik, 1981 ). The findings demonstrate that the virus responsible for the outbreak was derived from neither the live vaccine strain, nor from the type 3 strain which is the seed for the inactivated vaccine used in Finland.
The viruses isolated during the outbreak were antigenically heterogeneous when examined for neutralization by a large panel of monoclonal antibodies. Most of the strains were antigenically unusual, in that they were not neutralized by the majority of the antibodies tested, and the antigenic properties were consistent with the variations found in the sequence of the immunodominant antigenic site involved in the neutralization of the virus. It is, however, not clear why the heterogeneity arose, as this site is generally well conserved among unrelated type 3 viruses (Ferguson et al., , 1985 . It is possible that the epidemic began with an antigenically variant virus, which then evolved further under the immunological pressure of a population with only partial immunity to the initial strain. This view is supported by the observation that consecutive isolates from several persons showed different reaction patterns in neutralization tests with monoclonal antibodies (A. Huovilainen et al., unpublished results) .
The unusual antigenic nature of the virus isolates was reflected in the relative titres of human sera when tested against the seed strains used for the production of the inactivated vaccine or a strain from the outbreak. It was notable that sera from Sweden were of higher neutralization titre than those from Finland. Finland, Norway and Sweden all use inactivated vaccine, although from different sources.
Animals immunized with virus in a test similar to that used routinely to assess the potency of inactivated vaccine (European Pharmacopoeia, 1983) produced sera which were highly strainspecific. The two vaccine seed strains tested (Saukett E and Saukett F) were both ineffective in inducing neutralizing antibodies to the most antigenically drifted of the Finnish isolates (strain 23127). The potency of the inactivated vaccine used in Finland was five times greater than the minimum specified by the European Pharmacopoeia (1983) when the guinea-pig sera were tested with the Saukett or Sabin type 3 viruses, but failed when tested against 23127. These findings suggest that the potency of an inactivated vaccine as measured in the guinea-pig antigen test is strongly affected by both the strains of virus used to induce the antibody and those used to measure the response, and suggest a need to review the procedures for the potency testing of inactivated poliovirus.
The appearance of antigenically variant poliovirus type 3 strains in a vaccinated population emphasizes the continuing need for monitoring circulating strains of poliovirus for antigenic drift. It is noteworthy that only nine cases of poliovirus-associated disease occurred despite the widespread circulation of the virus in Finland (T. Hovi et al., unpublished results).
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